Biogen (BIIB) Cash from Investing Activities (2009 - 2026)

Biogen's Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$3.8 billion for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 6635.44% year-over-year to -$3.8 billion; the TTM figure through Jun 2026 stood at -$5.3 billion (down 307.63% YoY), while the FY2025 annual figure was -$1.4 billion, down 71.56% from the prior year.
• Cash from Investing Activities for Q2 2026 stood at -$3.8 billion, down from -$209.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $1.7 billion in Q3 2022, with the low at -$3.8 billion in Q2 2026.
• The 5-year median for Cash from Investing Activities is -$175.3 million (2022), against an average of -$485.7 million.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities soared 815.84% in 2022, then slumped 6635.44% in 2026.
• Biogen's Cash from Investing Activities stood at -$141.1 million in 2022, then sank by 362.3% to -$652.3 million in 2023, then soared by 97.15% to -$18.6 million in 2024, then plunged by 6522.04% to -$1.2 billion in 2025, then tumbled by 211.7% to -$3.8 billion in 2026.
• Business Quant data shows BIIB's Cash from Investing Activities at -$3.8 billion in Q2 2026, -$209.5 million in Q1 2026, and -$1.2 billion in Q4 2025.